Hyperactivity: a current assessment.

Hyperactivity in children is frequently overdiagnosed and inappropriately managed. When a syndrome of hyperactive behavior associated with learning difficulties is established, aggressive multifaceted management is indicated. Many possible etiologies have been suggested, but none of these has yet been proven. It may well be that more than one etiology exists and that many children have multiple factors contributing to their illness. None of the nontraditional therapies recently receiving attention, such as the Feingold diet, have had any proven benefit, although scattered anecdotal reports and some recent controlled trials suggest that some nontraditional therapies may be of limited value in some children. The most important consideration in therapy is that of defining specific problem areas for each individual child and assuring that each is dealt with appropriately. Caution must be exercised to avoid the pitfall of using drugs as the sole modality of treatment. Finally, parental education must never be overlooked.

Survival of pleomorphic sarcoma-37 transplanted virgin female DBA/2J mice: hyperthermia and hyperglycemia, alone and in combination with drugs.

Sarcoma-37 (S-37) transplanted DBA/2J mice were submitted to a controlled whole body hyperglycemic-hyperthermic ("double attack") treatment. A single exposure to the 3-hr 400-500-mg% blood glucose level coupled with 1 hr of whole body 40.0 degrees warming was safe and extended longevity by 40% over the nontreated controls. This increase suggests that additive or potentiated effects follow the two-parameter procedure. The treatment safety and resultant increased longevity were not enhanced by single-dose chemotherapy with doxorubicin and/or dacarbazine.

Survival of pleomorphic sarcoma-37 transplanted virgin female DBA/2J mice: effects produced by high blood glucose levels alone and in combination with drugs.

Procedures for producing, monitoring, and maintaining 3-hr 400-500-mg% whole blood glucose levels in Sarcoma-37 (S-37) transplanted virgin female inbred DBA/2J mice are described. Aqueous infused 40% (w/v) dextrose was evaluated as a potential therapeutic factor. The effects of procedural variations on treatment survival and longevity are discussed. One hundred percent infusion safety and 25% increased longevity over nontreated transplanted mice were achieved. Doxorubicin and/or dacarbazine were also evaluated when administered prior to the dextrose infusion. Doxorubicin followed by intravenous dextrose increased survivor longevity by 37%, but this combination was unsafe at the drug dosages employed. A large dose of dacarbazine was safe and effective alone but unsafe when given prior to the infusion, although the survivors lived 29% longer than the untreated transplanted controls. Both drugs were marginally effective, but safe, when given together. When given together prior to the infusion, only 87% survived the treatment. The survivors lived 6 days longer than the controls.